Getting in early and getting the 'bad news' out of the way before there should be some positivity with prosumer release and new tactical product in FY19. Forecast small positive EBITDA but NPAT will be significantly in the red due to depreciation & amortisation expenses from acquisitions in previous years.
The current negative sentiment around CAT will only get worse with this...what were the last couple of CR's done at?? $4 & $2 from memory?? Far from ideal...
It just appears that costs associated with driving this growth are so high...hard to justify when revenue growth was just 14% for H1.
What was the point of the CR presentation?? Just regurgitated the same info from the HY???
I'm a LTH and awaiting to see the impact of the new products from FY19 onwards but the time for talk is just about over.
They would want to hit revenue guidance for FY18...
Add to My Watchlist
What is My Watchlist?
